治疗急性髓性白血病的口服德平:评估对老年患者的疗效,安全性和未来影响
1Hematology Unit, S. Eugenio Hospital, Piazzale dell'Umanesimo, Rome, Italy.
Expert review of hematology
|March 31, 2025
概括
口服滴滴和滴滴 (C-DEC) 为老年急性髓性白血病 (AML) 患者提供了一种方便和有效的治疗方法. 这种低甲基化剂组合提供了与IV-DEC相似的疗效,增强了粘附性和减轻了负担.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 老年急性髓性白血病 (AML) 患者经常面临不良预后,不适合标准治疗.
- 二十年来,低甲基化剂 (HMA) 已成为AML管理的基石,最近与venetoclax.
- 甲素和甲素 (C-DEC) 的口服组合是静脉注射配方的替代品.
研究的目的:
- 审查服用德西他和雪达祖里丁 (C-DEC) 的口服组合,以治疗老年患者的AML.
- 讨论C-DEC的当前临床应用和正在进行的研究.
- 突出C-DEC在AML治疗中的潜在作用.
主要方法:
- 在AML患者中对C-DEC进行英语出版物的文献搜索通过PubMed.
- 包括在过去三年内发表的论文,直到2025年3月为最新信息.
- 专注于研究详细介绍C-DEC的疗效,安全性和施用方便性.
主要成果:
- C-DEC 证明了与静脉注射滴滴 (IV-DEC) 的治疗和药理等价性.
- 与IV-DEC相比,口服配方提供了增强的治疗坚持和降低患者负担.
- C-DEC提供了与IV-DEC相似的安全概况,并增加了便利性.
结论:
- C-DEC扩大了老年和不适合AML患者的治疗选择.
- 通过口服服用德平和扎里丁可以提高方便性和坚持性.
- 在急性髓性白血病的治疗中,C-DEC 是一种有价值的工具.
关键词:
在AML,AML就是AML.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.这就是QOLOL.临床治疗 临床治疗管理护理管理的护理.新型代理人 新型代理人年龄较大的患者.通过口服服用的迪西他.人们的生活质量.更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
相关概念视频
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...